Drug news
Tirasemtiv: no improvement found in respiratory function in patients with neurodegenerative disease
Cytokinetics has announced that is is ending development of tirasemtiv designed to treat amyotrophic lateral sclerosis (ALS) after it failed to improve respiratory function in patients with the neurodegenerative disease.
Its Phase III VITALITY-ALS study failed to meet its primary or any secondary endpoints. Results also showed more patients discontinued treatment with tirasemtiv than placebo due to non-serious tolerability issues related to the drug.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.